Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant for Vascular and Brain Health in Menopause
NCT07606664Phase 3Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
A Phase 3 trial of fezolinetant in vasomotor symptoms. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT07606664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606664.